Estrogen replacement therapy decreases platelet-activating factor-acetylhydrolase activity in post-menopausal women.
To examine the effects of estrogen replacement therapy on plasma platelet-activating factor-acetylhydrolase (PAF-AH) activity and the lipoprotein profile in post-menopausal women. Eight post-menopausal women received conjugated equine estrogen (0.625 mg/day) orally for a period of 10 weeks. PAF-AH activity and lipid levels were measured in plasma samples obtained from each subject prior to treatment and after 2, 6, and 10 weeks of estrogen therapy. Within 2 weeks of initiating estrogen treatment, a significant reduction in PAF-AH activity (-26%) was observed. Estrogen also caused significant decreases in total cholesterol (-8%), low-density lipoprotein-cholesterol (-24%), and the ratio of apolipoprotein B to A-II (-19%). On the other hand, levels of both high-density lipoprotein-cholesterol (18%) and triglyceride (31%) were elevated. Estrogen exerts a favorable effect on the lipoprotein profile, but decreased plasma PAF-AH activity may facilitate platelet aggregation thereby opposing protective effect of estrogen-replacement therapy with respect to thrombotic complications.